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Poster Session I S227severe opportunistic infections, a major cause of transplant related
mortality (Lang/ Handgretinger, BMT, 2008). We sought to deter-
mine engraftment, survival, IR, infection risk and frequency of
PTLD andGVHD in pediatrics recipients following CD34-selected
MUD PBSCT.
Methods:Pts# 30 yrs requiring aMUD transplant for selectivema-
lignant and nonmalignant disease who were eligible. HLA matching
included 8/10, 9/10 and 10/10 at intermediate resolutionHLAA and
B and high resolution HLA C, DRB1 and D2. Isolex 300i (Nexell,
Irvine, CA) immunomagnetic cell selection system was used for
CD34 selection with a goal of achieving $ 5 x106 CD34/kg
PBSC. T cells were added back to reach a total CD3 dose of
1.0-2.6x105/kg. GVHD prophylaxis consisted only of tacrolimus
(Bhatia/Cairo et al, BBMT, 2010). Supportive care was as we have
previously described (Bradley/Cairo, BMT, 2007).
Results: 19 pts, median f/u: 534d, median age: 15.3 yrs (10-23); 12:7
M:F, HLAmatch 26% 10/10, 31% 9/10, 42% 8/10; 68%malignant.
Infused grafts contained amedian of 1.6x105CD31/kg (0.1-4.8) and
5.1x106CD341/kg (2.0-13.3). Probabilities of neutrophil and plate-
let engraftment, grade II-IV aGVHD, cGVHD and day 100 TRM
were 100%, 82.3%, 15.8%, 24.2% and 0%, respectively. CD3,
CD4, CD8, CD19 and CD56 counts at day1180/365 reached nor-
mal in 11/30, 0/15, 22/46, 56/76 and 94/100% of patients, respec-
tively. IgG, IgM, and IgA reached normal in 47/50, 59/50, and 59/
33% of patients, respectively. One pt (5.2%) developed PTLD. 11
donor/pts were CMV positive, and 2 pts experienced CMV SVI.
The 1-yr probability of developing SVI and IFI was 42.3% and
28.0%, respectively. Despite the high incidence of SVI and IFI,
the 1-yr probability of mortality due to SVI and IFI was 5.3%
(CI95: 0-65%) and of OS was 84.2% (CI95: 59-95).
Conclusions: Rapid neutrophil engraftment, low rate of PTLD,
aGVHD/ cGVHD, and low day 100 TRMwere observed. Although
immune reconstitution was not mature at 1 yr post transplant, the
overall probability of infection related mortality was relatively low.
These results support continued investigation of CD34-selected
MUD PBSCT in selective pediatric AlloSCT recipients.201
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Hematopoietic stem cell transplants have been performed mostly
from matched related or unrelated donors (MUD). Given the racial
composition of the unrelated donor registries, it has been difficult
to identify a MUD for non-Caucasian patients (pts). A review of all
the MUD pts transplanted at MD Anderson (MDACC) past 25
years revealed that of 2117 pts, 1677 (79.2%) were whites (W),
271 pts (12.8%) Hispanics (H), 109 (5%) Afican-Americans (AA)
and 33 (1.5%) were Asians (A). Similar racial distribution was noted
with pts receiving a 9/10 MUD during the same period of time.
We hypothesized that haploidentical stem cell transplantation
(HaploSCT) would be an alternative for the minorities without
a matched donor and treated 24 consecutive pts with a conditioning
regimen consisting of fludarabine (40mg/m2/day  4), melphalan
(140mg/m2) and thiotepa (10mg/kg). 4 pts . 55 years/comorbid-
ities received a RIC with fludarabine and lower doses of melphalan
(100mg/m2) and thiotepa (5mg/kg). GVHD prophylaxis consisted
of post transplant cyclophosphamide (50mg/kg/day  2), tacroli-
mus and mycophenolate.
Results: Racial distribution in this group was 8/24 (33.3%) W, 6/
24 (25%) H, 5/24 (21%) AA, 4/24 (16.6%) A, 1/24 (4%) other, for
a total of 66.6% minority population. Median age was 47 years (24-
65). All pts but one received bone marrow stem cells. 4 pts had
prior allogeneic transplants. 13 pts had AML/MDS (8 poor-risk cy-
togenetics), 6 pts had CML/MPD (5/5 blast phase CML), 5 pts had
lymphoma/CLL. Donor-recipient HLA matching was: 5/10 in 12
pts (50%), 6/10 in 3/25 pts (12%), 7/10 in 5/25 pts (20%) and 8/
10 in 4/25 (16%). 10 pts (42%) were in remission at the time of
transplant. All 23 evaluable pts (one had early death) engraftedwith 100% donor chimerism (100% engraftment) after a median
of 19 days (5-40). Cumulative incidence of day-100 treatment-re-
lated mortality (TRM) was 14%. No patients less than 50 years
died of TRM. Grade II-IV aGVHD occurred in 4 patients and
cGVHD in 1 patient. 7/18 (39%) pts relapsed while only 1 for
the pts in remission at the time of transplant. After a median fol-
low-up of 6 months (range 3-18) for survivors of . 100 days
(N 5 14), OS for the whole group was 80%, while PFS for pts
in remission at the time of transplant was 89% (N 5 10, CI
43-98%). No differences in OS/PFS were noted between the
Caucasian and non-Caucasian population.
Conclusion: HaploSCT is a feasible and safe transplant alternative
for minority pts who lack a matched donor.202
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Objective:Toevaluate the safety and efficacy of haploidenticalHCT
(h-HCT) with T-cell depleted graft in children and adolescents
Patients and methods: Between July 2008 and April 2010, 11 pa-
tients received allogeneic PBSCT from mismatched family donors.
Of 11 patients, 6 had SAA (5 acquired, 1 Fanconi anemia), and
5 had hematologic malignancy (HM), of which 3 were AML (1
CR2, 1 refractory, 1 graft failure after CBT), 1 was ALL in CR3,
and 1 was MDS-RA. A total of 13 h-HSCTs were performed in
11 patients. All 13 cases were conditioned with non-myeloablative
regimen containing fludarabine, and busulfan at a dose of 8mg/kg
was added for hematologic malignancies. ATG was also included
except for cases of graft failure and none of enrolled patients re-
ceived any kind of irradiation. The mobilized and collected product
was processed for CD3 alone or CD3/CD19 depletion using
CliniMACS.
Results:Of 11 patients, 9 achieved neutrophil engraftment at a me-
dian of 11 days of whom 2 experienced late graft failure (GF) on
day 125 and 1200, respectively. Four patients developed acute
GVHD of grade II and none had . II aGVHD. Of 4 patients
who experienced GF (2 primary and 2 late), 2 received the 2nd
h-HCT from different donors and all 2 are alive with complete do-
nor chimerism. At a median follow-up of 12.2 (5.927.7) months,
all 11 patients are alive. Of 6 patients with SAA, 4 are well and alive
in a complete donor chimerism without transfusion (TF) need, 1
remains on infrequent need of TF with 95% donor chimerism at
day 1221, and 1 received a 2nd h-HCT for primary GF, after
which the patient remains on infrequent need of TF with full donor
chimerism at day 1145. Of 5 patients with HM, 3 patients with
AML are alive in CR at days 1178, 1412, and 1812, respectively,
although 1 of those experienced late graft failure. The remaining 2
patients are alive with disease at days 1334 and 1377, respectively,
of whom 1 with MDS experienced 1 GF and the other with ALL
relapsed at day 1269. Although no infection-related death
occurred, most of the patients had a viral reactivation or disease, in-
cluding PTLD and CMV retinitis.
Conclusions:TheHCT using haploidentical family donors is a fea-
sible option for children with diseases curable with HCT, but lack
a suitable related or unrelated donor. However, graft failure and in-
fection are still obstacles to overcome to improve the outcome of
hHCT in children and adolescents.203
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